XML 286 R42.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Financing (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Debt Disclosure [Abstract] |
Components Of Debt | The components of the Company’s debt as of December 31 were as follows (amounts in millions):
|  | Outstanding Amount |  |
Description and Aggregate Principal Amount |  | 2021 |  | 2020 |  |
U.S. dollar-denominated commercial paper |  | $ | 1,440 |  |  | $ | — |  |  |
Euro-denominated commercial paper (€1.2 billion and €500 million, respectively) |  | 1,366 |  |  | 611 |  |  |
Zero-coupon LYONs due 1/22/2021 |  | — |  |  | 24 |  |  |
0.352% senior unsecured notes due 3/16/2021 (¥30.0 billion) (the “2021 Yen Notes”) |  | — |  |  | 290 |  |  |
Floating rate senior unsecured notes due 6/30/2022 (€250 million) (the “Floating Rate 2022 Euronotes”) |  | 284 |  |  | 305 |  |  |
2.05% senior unsecured notes due 11/15/2022 (the “2022 Biopharma Notes”) |  | 699 |  |  | 698 |  |  |
0.5% senior unsecured bonds due 12/08/2023 (CHF 540 million) (the “2023 CHF Bonds”) |  | 592 |  |  | 611 |  |  |
1.7% senior unsecured notes due 3/30/2024 (€900 million) (the “2024 Euronotes”) |  | 1,021 |  |  | 1,096 |  |  |
2.2% senior unsecured notes due 11/15/2024 (the “2024 Biopharma Notes”) |  | 698 |  |  | 697 |  |  |
2.5% senior unsecured notes due 7/08/2025 (€800 million) (the “2025 Euronotes”) |  | — |  |  | 975 |  |  |
3.35% senior unsecured notes due 9/15/2025 (the “2025 U.S. Notes”) |  | 498 |  |  | 498 |  |  |
0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”) |  | 1,416 |  |  | 1,520 |  |  |
2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”) |  | 907 |  |  | 975 |  |  |
0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”) |  | 267 |  |  | 297 |  |  |
1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”) |  | 680 |  |  | 729 |  |  |
0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”) |  | 1,413 |  |  | 1,518 |  |  |
1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”) |  | 233 |  |  | 241 |  |  |
2.6% senior unsecured notes due 11/15/2029 (the “2029 Biopharma Notes”) |  | 795 |  |  | 795 |  |  |
2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”) |  | 910 |  |  | 978 |  |  |
0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”) |  | 1,980 |  |  | 2,127 |  |  |
0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”) |  | 461 |  |  | 514 |  |  |
1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”) |  | 1,406 |  |  | 1,511 |  |  |
3.25% senior unsecured notes due 11/15/2039 (the “2039 Biopharma Notes”) |  | 890 |  |  | 889 |  |  |
4.375% senior unsecured notes due 9/15/2045 (the “2045 U.S. Notes”) |  | 499 |  |  | 499 |  |  |
1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”) |  | 844 |  |  | 907 |  |  |
3.4% senior unsecured notes due 11/15/2049 (the “2049 Biopharma Notes”) |  | 889 |  |  | 889 |  |  |
2.6% senior unsecured notes due 10/01/2050 (the “2050 U.S. Notes”) |  | 980 |  |  | 979 |  |  |
2.8% senior unsecured notes due 12/10/2051 (the “2051 U.S. Notes”) |  | 983 |  |  | — |  |  |
Other |  | 25 |  |  | 31 |  |  |
Total debt |  | 22,176 |  |  | 21,204 |  |  |
Less: currently payable |  | (8) |  |  | (11) |  |  |
Long-term debt |  | $ | 22,168 |  |  | $ | 21,193 |  |  |
The following summarizes the key terms of the offerings in aggregate ($ in millions):
| Issue Date |  | Aggregate Principal Amount |  | Stated Annual Interest Rate |  | Issue Price (as % of Principal Amount) |  | Maturity Date |  | Interest Payment Dates (in arrears)
2051 U.S. Notes | December 10, 2021 |  | $ | 1,000 |  |  | 2.8 | % |  | 99.396 | % |  | December 10, 2051 |  | June 10 and December 10
Schedule of Maturities of Long-term Debt | The Company’s minimum principal payments for the next five years are as follows ($ in millions):
2022 | $ | 8 |
2023 | 4,367 |
2024 | 1,710 |
2025 | 490 |
2026 | 2,323 |
Thereafter | 13,278 |

X
- References No definition available. + Details
Name: | us-gaap_DebtDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69B -URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69E -URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644 Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823 Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644 + Details
Name: | us-gaap_ScheduleOfDebtInstrumentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of maturity and sinking fund requirement for long-term debt. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601 + Details
Name: | us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration